Pharmacyte Biotech Inc (PMCB) 0.1084 $PMCB
PharmaCyte Biotech Hosts 2nd Annual Meeting of International Diabetes Consortium Developing Novel Treatment for Diabetes
GlobeNewswire - Thu Oct 29, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that PharmaCyte held the second annual meeting of its "International Diabetes Consortium" in Vienna, Austria, to review data that has been generated by the Consortium and update its strategic plan for the development of PharmaCyte's treatment for insulin dependent diabetes.
Quantified Self: MyDx Targets a Growing Multi-Billion Dollar Industry
ACCESSWIRE - Tue Oct 27, 8:24AM CDT
SEATTLE, WA / ACCESSWIRE / October 27, 2015 / The quantified self movement has been rapidly expanding over the past several years, as consumers embrace its "if you can measure it, you can change it" principles. According to IHS, the global market for wearables and sensors will rise to 210 million units shipped and $30 billion in revenue by 2018, while companies like FitBit Inc. (NYSE: FIT) and Apple Inc. (NASDAQ: AAPL) are already making millions of dollars each quarter selling early-stage technology.
FIT: 40.54 (+2.97), ABT: 44.80 (-0.44), GWPH: 79.09 (-1.87), AAPL: 119.50 (-1.03)
PharmaCyte Biotech Due Diligence Report - Technology Gets an Industry Boost - Small Cap Street
PR Newswire - Tue Oct 27, 7:15AM CDT
PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed at $.10 off 5.66% in yesterday's session. Trading volume was 3 million shares, somewhat over the daily average of 2 million shares traded. PMCB shares had jumped 75% from mid-September to mid-October before investors took some profits over the past two weeks.
PharmaCyte Biotech Management Interviewed to Discuss Key Aspects of New Pancreatic Cancer Clinical Trial Design
GlobeNewswire - Fri Oct 23, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the release of a recorded interview with Chief Executive Officer Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree that highlights the key aspects of PharmaCyte's new pancreatic cancer clinical trial design.
A Look Behind the Curtain - Research on PetroTerra, Kirin International Holdings, Force Protection Video Equipment, Black Stallion Oil & Gas, and PharmaCyte Biotech
ACCESSWIRE - Thu Oct 22, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 22, 2015 / Moments ago, ACI Association released new research updates concerning several important developing situations including the following equities: Petroterra Corp (OTC: PTRA), Kirin International Holding Inc. (OTC: KIRI), Force Protection Video Equipment Corp (OTC: FPVD), Black Stallion Oil and Gas Inc. (OTC: BLKG), and Pharmacyte Biotech Inc. (OTC: PMCB). ACI Association provides a single unified platform for investors to hear about what matters. The full research reports are being made available to the public on a complimentary basis.
PharmaCyte Biotech Clinical Trial Designed to Expand Standard of Care Therapy for Pancreatic Cancer
GlobeNewswire - Wed Oct 21, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the new trial design for its upcoming clinical trial in patients with advanced pancreatic cancer using PharmaCyte's treatment (Cell-in-a-Box+ low-dose ifosfamide chemotherapy).
PharmaCyte Biotech's Cell Encapsulation Technology at the Forefront of Future Diabetes Treatments
PR Newswire - Tue Oct 20, 8:15AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it and previous articles in their entirety, please visit http://www.GoldmanResearch.com.
PharmaCyte Biotech to Conduct Pancreatic Cancer Clinical Trial in United States
GlobeNewswire - Mon Oct 19, 8:49AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that its upcoming clinical trial designed to determine whether its pancreatic cancer treatment (Cell-in-a-Box capsules + low-doses ifosfamide chemotherapy) can satisfy a critical unmet medical need for patients with pancreatic cancer will be conducted in the United States with additional study sites in Europe and Australia.
Penny Stocks Alerts for Terra Tech, MannKind, Pharmacyte Biotech, GT Advanced Technologies, EKSO BIONICS, and Baltia Air Lines
PR Newswire - Fri Oct 16, 9:15AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Terra Tech (OTCMKTS:TRTC), MannKind (NASDAQ:MNKD), Pharmacyte Biotech (OTCMKTS MCB), GT Advanced Technologies (OTCMKTS:GTATQ), EKSO BIONICS (OTCBB:EKSO), and Baltia Air Lines (OTCMKTS:BLTA).
MNKD: 3.31 (-0.15)
PharmaCyte Biotech Aims for Consolidated Therapy to Address Unmet Medical Need in Upcoming Cancer Clinical Trial
Marketwired - Thu Oct 15, 8:25AM CDT
PharmaCyte Biotech's (OTCQB: PMCB) advanced pancreatic cancer treatment of Cell-in-a-Box® capsules + low-doses of ifosfamide has outperformed Eli Lilly's anti-cancer chemotherapy drug Gemzar® or gemcitabine in early phase clinical trials when compared to historical data for gemcitabine in 3 key areas: median survival time, one-year survivors and harmful side effects. PharmaCyte's treatment also showed better data in those same 3 areas in early phase trials than Celgene's Abraxane® plus gemcitabine, the current "gold standard," offers patients.
LLY: 81.57 (-0.43), CELGZ: 1.65 (+0.17)
PharmaCyte Biotech Designs Clinical Trial to Meet Critical Unmet Medical Need
GlobeNewswire - Wed Oct 14, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that its upcoming clinical trial will determine whether its pancreatic cancer treatment (Cell-in-a-Box capsules + low-doses of ifosfamide) can satisfy a critical unmet medical need for patients with pancreatic cancer when the "gold standard" treatment is no longer effective at treating the disease. Currently there is no adequate alternative treatment available.
Investor Update: PharmaCyte Biotech Due Diligence Report - Small Cap Street
PR Newswire - Tue Oct 13, 12:00PM CDT
PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed at $.1035, off 3.09% in yesterday's session. Trading volume was at near average with 1,308,352 shares being traded. PMCB shares have been soft in the second half of this year hitting a low of $.072 in September, then bouncing back to current levels.
PharmaCyte Biotech Cell Encapsulation Technology Could Re-Shape and Lead Advancements in Diabetes Treatments
PR Newswire - Tue Oct 13, 9:23AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB: PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it and previous articles in their entirety, please visit http://www.GoldmanResearch.com.
Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now Securing Europe for Pancreatic Cancer Treatment
Marketwired - Fri Oct 09, 8:25AM CDT
The combination of PharmaCyte Biotech's (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box® with low doses of ifosfamide has already won the FDA's "Orphan Drug" status here in the U.S., and now it seems the company will also be awarded the "Orphan Designation" with the European Medicines Agency (EMA), which would guarantee 10 years of competition-free marketing when the pancreatic cancer treatment is approved.
Undervalued PharmaCyte Biotech Moves Closer to Phase 2b Clinical Trial Launch Featuring Breakthrough Technology
PR Newswire - Thu Oct 08, 8:15AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new sponsored research report on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research report, along with disclosures and disclaimers, or to download it and previous articles in their entirety, please visit http://www.GoldmanResearch.com.
PharmaCyte Biotech CEO in Europe to Secure Orphan Designation With the EMA
GlobeNewswire - Wed Oct 07, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, announced today that Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, is currently in Europe ironing out the details that will secure the European Medicines Agency (EMA) Orphan Designation for PharmaCyte Biotech's pancreatic cancer treatment.
Imaging Endpoints Founder Discusses Role in PharmaCyte Biotech's Unique Approach to Pancreatic Cancer for Upcoming Clinical Trial
GlobeNewswire - Mon Oct 05, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, released today the third in a series of articles that will serve to educate the public on its technology and how it is used in the treatment of advanced pancreatic cancer. This latest article is written by Dr. Ronald L. Korn, MD, Ph.D., who is the Founder, Chairman and Chief Medical Officer of Imaging Endpoints in Scottsdale, Arizona. Imaging Endpoints is the company that will perform the radiologic imaging that will be required for PharmaCyte Biotech's upcoming Phase 2b clinical trial in pancreatic cancer.
PharmaCyte Biotech Retains Industry Expert to Monitor Short Sellers and Market Makers
GlobeNewswire - Thu Oct 01, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell in a Box, announced today that BUYINS.NET, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Pharmacyte Biotech after releasing the latest short sale data through September 29, 2015. BUYINS.NET will monitor the market makers of PharmaCyte Biotech's stock daily for compliance with fair market-making requirements.
BUYINS.NET Issues PharmaCyte Biotech (PMCB) SqueezeTrigger Report
M2 - Thu Oct 01, 7:39AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Pharmacyte Biotech (OTC: PMCB) after releasing the latest short sale data through September 29, 2015. The total aggregate number of shares shorted since August 2009 is approximately 916 million shares. Approximately 34.76% of daily trading volume is short selling. The SqueezeTrigger price for all PMCB shares shorted is $.1838. A short squeeze is expected to begin when the stock closes above the $.1838 SqueezeTrigger price.
PharmaCyte Biotech Moves Closer to Revealing Plan to Address Unmet Medical Need in Phase 2b Clinical Trial
Marketwired - Wed Sep 30, 8:30AM CDT
Cancer is the world's second most common cause of death, not too far behind heart disease. And, although no form of cancer is "good," pancreatic cancer is perhaps the least treatable and most discouraging, taking the lives of more than 86% of its victims within five years of being diagnosed. PharmaCyte Biotech Inc. (OTCQB: PMCB) is developing a treatment regimen that could significantly address this unmet medical need.
PharmaCyte Biotech Hosts 2nd Annual Meeting of International Diabetes Consortium Developing Novel Treatment for Diabetes
GlobeNewswire - Thu Oct 29, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that PharmaCyte held the second annual meeting of its "International Diabetes Consortium" in Vienna, Austria, to review data that has been generated by the Consortium and update its strategic plan for the development of PharmaCyte's treatment for insulin dependent diabetes. Quantified Self: MyDx Targets a Growing Multi-Billion Dollar Industry
ACCESSWIRE - Tue Oct 27, 8:24AM CDT
SEATTLE, WA / ACCESSWIRE / October 27, 2015 / The quantified self movement has been rapidly expanding over the past several years, as consumers embrace its "if you can measure it, you can change it" principles. According to IHS, the global market for wearables and sensors will rise to 210 million units shipped and $30 billion in revenue by 2018, while companies like FitBit Inc. (NYSE: FIT) and Apple Inc. (NASDAQ: AAPL) are already making millions of dollars each quarter selling early-stage technology.
FIT: 40.54 (+2.97), ABT: 44.80 (-0.44), GWPH: 79.09 (-1.87), AAPL: 119.50 (-1.03)
PharmaCyte Biotech Due Diligence Report - Technology Gets an Industry Boost - Small Cap Street
PR Newswire - Tue Oct 27, 7:15AM CDT
PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed at $.10 off 5.66% in yesterday's session. Trading volume was 3 million shares, somewhat over the daily average of 2 million shares traded. PMCB shares had jumped 75% from mid-September to mid-October before investors took some profits over the past two weeks.
PharmaCyte Biotech Management Interviewed to Discuss Key Aspects of New Pancreatic Cancer Clinical Trial Design
GlobeNewswire - Fri Oct 23, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the release of a recorded interview with Chief Executive Officer Kenneth L. Waggoner and Chief Operating Officer Dr. Gerald W. Crabtree that highlights the key aspects of PharmaCyte's new pancreatic cancer clinical trial design. A Look Behind the Curtain - Research on PetroTerra, Kirin International Holdings, Force Protection Video Equipment, Black Stallion Oil & Gas, and PharmaCyte Biotech
ACCESSWIRE - Thu Oct 22, 8:00AM CDT
NEW YORK, NY / ACCESSWIRE / October 22, 2015 / Moments ago, ACI Association released new research updates concerning several important developing situations including the following equities: Petroterra Corp (OTC: PTRA), Kirin International Holding Inc. (OTC: KIRI), Force Protection Video Equipment Corp (OTC: FPVD), Black Stallion Oil and Gas Inc. (OTC: BLKG), and Pharmacyte Biotech Inc. (OTC: PMCB). ACI Association provides a single unified platform for investors to hear about what matters. The full research reports are being made available to the public on a complimentary basis.
PharmaCyte Biotech Clinical Trial Designed to Expand Standard of Care Therapy for Pancreatic Cancer
GlobeNewswire - Wed Oct 21, 8:20AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today the new trial design for its upcoming clinical trial in patients with advanced pancreatic cancer using PharmaCyte's treatment (Cell-in-a-Box+ low-dose ifosfamide chemotherapy). PharmaCyte Biotech's Cell Encapsulation Technology at the Forefront of Future Diabetes Treatments
PR Newswire - Tue Oct 20, 8:15AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it and previous articles in their entirety, please visit http://www.GoldmanResearch.com.
PharmaCyte Biotech to Conduct Pancreatic Cancer Clinical Trial in United States
GlobeNewswire - Mon Oct 19, 8:49AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that its upcoming clinical trial designed to determine whether its pancreatic cancer treatment (Cell-in-a-Box capsules + low-doses ifosfamide chemotherapy) can satisfy a critical unmet medical need for patients with pancreatic cancer will be conducted in the United States with additional study sites in Europe and Australia. Penny Stocks Alerts for Terra Tech, MannKind, Pharmacyte Biotech, GT Advanced Technologies, EKSO BIONICS, and Baltia Air Lines
PR Newswire - Fri Oct 16, 9:15AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Terra Tech (OTCMKTS:TRTC), MannKind (NASDAQ:MNKD), Pharmacyte Biotech (OTCMKTS
MCB), GT Advanced Technologies (OTCMKTS:GTATQ), EKSO BIONICS (OTCBB:EKSO), and Baltia Air Lines (OTCMKTS:BLTA). MNKD: 3.31 (-0.15)
PharmaCyte Biotech Aims for Consolidated Therapy to Address Unmet Medical Need in Upcoming Cancer Clinical Trial
Marketwired - Thu Oct 15, 8:25AM CDT
PharmaCyte Biotech's (OTCQB: PMCB) advanced pancreatic cancer treatment of Cell-in-a-Box® capsules + low-doses of ifosfamide has outperformed Eli Lilly's anti-cancer chemotherapy drug Gemzar® or gemcitabine in early phase clinical trials when compared to historical data for gemcitabine in 3 key areas: median survival time, one-year survivors and harmful side effects. PharmaCyte's treatment also showed better data in those same 3 areas in early phase trials than Celgene's Abraxane® plus gemcitabine, the current "gold standard," offers patients.
LLY: 81.57 (-0.43), CELGZ: 1.65 (+0.17)
PharmaCyte Biotech Designs Clinical Trial to Meet Critical Unmet Medical Need
GlobeNewswire - Wed Oct 14, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, announced today that its upcoming clinical trial will determine whether its pancreatic cancer treatment (Cell-in-a-Box capsules + low-doses of ifosfamide) can satisfy a critical unmet medical need for patients with pancreatic cancer when the "gold standard" treatment is no longer effective at treating the disease. Currently there is no adequate alternative treatment available.
Investor Update: PharmaCyte Biotech Due Diligence Report - Small Cap Street
PR Newswire - Tue Oct 13, 12:00PM CDT
PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed at $.1035, off 3.09% in yesterday's session. Trading volume was at near average with 1,308,352 shares being traded. PMCB shares have been soft in the second half of this year hitting a low of $.072 in September, then bouncing back to current levels.
PharmaCyte Biotech Cell Encapsulation Technology Could Re-Shape and Lead Advancements in Diabetes Treatments
PR Newswire - Tue Oct 13, 9:23AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB: PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it and previous articles in their entirety, please visit http://www.GoldmanResearch.com.
Armed With FDA Orphan Drug Status in the U.S., PharmaCyte Biotech Now Securing Europe for Pancreatic Cancer Treatment
Marketwired - Fri Oct 09, 8:25AM CDT
The combination of PharmaCyte Biotech's (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box® with low doses of ifosfamide has already won the FDA's "Orphan Drug" status here in the U.S., and now it seems the company will also be awarded the "Orphan Designation" with the European Medicines Agency (EMA), which would guarantee 10 years of competition-free marketing when the pancreatic cancer treatment is approved.
Undervalued PharmaCyte Biotech Moves Closer to Phase 2b Clinical Trial Launch Featuring Breakthrough Technology
PR Newswire - Thu Oct 08, 8:15AM CDT
Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new sponsored research report on PharmaCyte Biotech, Inc. (OTCQB - PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research report, along with disclosures and disclaimers, or to download it and previous articles in their entirety, please visit http://www.GoldmanResearch.com.
PharmaCyte Biotech CEO in Europe to Secure Orphan Designation With the EMA
GlobeNewswire - Wed Oct 07, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, announced today that Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech, is currently in Europe ironing out the details that will secure the European Medicines Agency (EMA) Orphan Designation for PharmaCyte Biotech's pancreatic cancer treatment. Imaging Endpoints Founder Discusses Role in PharmaCyte Biotech's Unique Approach to Pancreatic Cancer for Upcoming Clinical Trial
GlobeNewswire - Mon Oct 05, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, released today the third in a series of articles that will serve to educate the public on its technology and how it is used in the treatment of advanced pancreatic cancer. This latest article is written by Dr. Ronald L. Korn, MD, Ph.D., who is the Founder, Chairman and Chief Medical Officer of Imaging Endpoints in Scottsdale, Arizona. Imaging Endpoints is the company that will perform the radiologic imaging that will be required for PharmaCyte Biotech's upcoming Phase 2b clinical trial in pancreatic cancer. PharmaCyte Biotech Retains Industry Expert to Monitor Short Sellers and Market Makers
GlobeNewswire - Thu Oct 01, 8:25AM CDT
PharmaCyte Biotech, Inc. (OTCQB
MCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell in a Box, announced today that BUYINS.NET, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Pharmacyte Biotech after releasing the latest short sale data through September 29, 2015. BUYINS.NET will monitor the market makers of PharmaCyte Biotech's stock daily for compliance with fair market-making requirements. BUYINS.NET Issues PharmaCyte Biotech (PMCB) SqueezeTrigger Report
M2 - Thu Oct 01, 7:39AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Pharmacyte Biotech (OTC: PMCB) after releasing the latest short sale data through September 29, 2015. The total aggregate number of shares shorted since August 2009 is approximately 916 million shares. Approximately 34.76% of daily trading volume is short selling. The SqueezeTrigger price for all PMCB shares shorted is $.1838. A short squeeze is expected to begin when the stock closes above the $.1838 SqueezeTrigger price.
PharmaCyte Biotech Moves Closer to Revealing Plan to Address Unmet Medical Need in Phase 2b Clinical Trial
Marketwired - Wed Sep 30, 8:30AM CDT
Cancer is the world's second most common cause of death, not too far behind heart disease. And, although no form of cancer is "good," pancreatic cancer is perhaps the least treatable and most discouraging, taking the lives of more than 86% of its victims within five years of being diagnosed. PharmaCyte Biotech Inc. (OTCQB: PMCB) is developing a treatment regimen that could significantly address this unmet medical need.
